ObjectiveWe hypothesized that clinical outcome of resected early-stage adenocarcinoma of the lung can be predicted by the expression of a few critically important genes as measured by quantitative real-time reverse-transcriptase polymerase chain reaction in formalin-fixed paraffin-embedded primary tumors.MethodsTwenty-two prognostic genes for the metastatic phenotype were identified through complementary DNA microarray analysis of 4 cancer cell lines and bioinformatics analysis. Expression levels of a subset of these genes (n = 13) were measured by real-time time reverse-transcriptase polymerase chain reaction in formalin-fixed paraffin-embedded primary adenocarcinoma from patients whose disease recurred within 2 years (n = 9) and in patien...
Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because...
Terapias adyuvantes; Cáncer de pulmón; PronósticoTeràpies adjuvants; Càncer de pulmó; PronòsticAdjuv...
Background: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, ...
IntroductionThe aim of this study was to validate a molecular expression signature [cell cycle progr...
Introduction The aim of this study was to validate a molecular expression signature [cell cycle prog...
BACKGROUND: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, ...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
IntroductionThis prospective study aimed to develop a robust and clinically applicable method to ide...
Introduction: The aim of this study was to validate a molecular expression signature [cell cycle pro...
OBJECTIVES: Optimal procedures for adjuvant treatment and post-surgical surveillance of resected non...
Risk assessment and treatment choice remains a challenge in early non-smallcell lung cancer (NSCLC)....
Adenocarcinoma is the predominant histological subtype of lung cancer, the leading cause of cancer d...
Prognostic tests for patients with early-stage lung cancer may provide needed guidance on postoperat...
BackgroundPrognostic biomarkers are needed in clinical setting to predict outcome after resection fo...
BackgroundPrognostic biomarkers are needed in clinical setting to predict outcome after resection fo...
Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because...
Terapias adyuvantes; Cáncer de pulmón; PronósticoTeràpies adjuvants; Càncer de pulmó; PronòsticAdjuv...
Background: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, ...
IntroductionThe aim of this study was to validate a molecular expression signature [cell cycle progr...
Introduction The aim of this study was to validate a molecular expression signature [cell cycle prog...
BACKGROUND: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, ...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
IntroductionThis prospective study aimed to develop a robust and clinically applicable method to ide...
Introduction: The aim of this study was to validate a molecular expression signature [cell cycle pro...
OBJECTIVES: Optimal procedures for adjuvant treatment and post-surgical surveillance of resected non...
Risk assessment and treatment choice remains a challenge in early non-smallcell lung cancer (NSCLC)....
Adenocarcinoma is the predominant histological subtype of lung cancer, the leading cause of cancer d...
Prognostic tests for patients with early-stage lung cancer may provide needed guidance on postoperat...
BackgroundPrognostic biomarkers are needed in clinical setting to predict outcome after resection fo...
BackgroundPrognostic biomarkers are needed in clinical setting to predict outcome after resection fo...
Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because...
Terapias adyuvantes; Cáncer de pulmón; PronósticoTeràpies adjuvants; Càncer de pulmó; PronòsticAdjuv...
Background: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, ...